GCell Withdraws Clinical Trial for Acute Respiratory Distress Syndrome Stem Cell Therapy
GC Cell voluntarily withdrew the clinical trial plan for CT303, an allogeneic tonsil-derived mesenchymal stem cell candidate for acute respiratory distress syndrome (ARDS) treatment.
On the 12th, GC Cell announced through a public disclosure that the Phase 1 domestic clinical trial of CT303, approved by the Ministry of Food and Drug Safety in October 2021 and scheduled to be conducted at three domestic hospitals including Seoul National University Hospital, was completed on February 20 of this year.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
GC Cell explained that after the clinical trial plan approval, efforts were made to recruit patients at the three hospitals; however, most ARDS patients were elderly with previous medical histories, and due to a shortage of medical staff and difficulties securing intensive care units caused by COVID-19, no trial participants were registered.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
